基于孟德尔随机化探究肾小球滤过率与心血管疾病结局的因果关系
Exploring the Causal Relationship between Estimated Glomerular Filtration Rate and Cardiovascular Disease Outcomes Based on Mendelian Randomization
DOI: 10.12677/acm.2025.151193, PDF,    科研立项经费支持
作者: 黄烁萱, 缪长宏, 王怡寒, 肖 璐, 陈 匡*:天津中医药大学第一附属医院/国家中医针灸临床医学研究中心,天津;天津中医药大学,天津
关键词: 孟德尔随机化肾小球滤过率心力衰竭心血管疾病因果关系Mendelian Randomization Glomerular Filtration Rate Heart Failure Cardiovascular Disease Causality
摘要: 背景:目前大量观察性研究表明估算肾小球滤过率(eGFR)下降与心血管疾病风险增加有关。但是对于估算肾小球滤过率与心血管疾病之间的潜在关系还没有统一的结论。方法:我们首先从一项全基因组关联研究(GWAS)中确定了估算肾小球滤过率的遗传工具。我们利用MR分析对不同心血管结局事件进行了双样本的分析,并采用逆方差加权、加权中位数、MR-PRESSO、MR-egger和留一法进行分析。结果:研究结果显示,经最严格的Bonferroni矫正后(Padjust = 0.01),肾小球滤过率估计值降低与心力衰竭之间的潜在因果关系有显著证据,IVW结果提示有显著统计学意义(OR = 1.009, 95%CI = 1.003~1.015, P = 0.003, P < Padjust)。在估算肾小球滤过率与冠状动脉综合征(CAD) (OR = 1.006, 95%CI = 0.998~1.013, P = 0.14)、估算肾小球滤过率与心血管疾病(CVD) (OR = 1.003, 95%CI = 0.995~1.011, P = 0.45)、估算肾小球滤过率与卒中(OR = 1.000, 95%CI = 0.9998~1.0001, P = 0.95)以及估算肾小球滤过率与心房颤动(AF) (OR = 1.004, 95%CI = 0.9952~1.0126, P = 0.38)的IVW试验结果均未提示eGFR与心血管结局事件之间存在潜在的因果关系。结论:我们进行的多个大型MR分析发现,估算肾小球滤过率与心衰发生的风险存在显著的因果关系,但是我们未发现估算肾小球滤过率对于其他心血管结局事件有显著因果关联。
Abstract: Background: A large number of observational studies have shown that a decrease in estimated glomerular filtration rate (eGFR) is associated with an increased risk of cardiovascular disease. However, there is no consensus on the potential relationship between eGFR and cardiovascular diseases. Methods: We first identified genetic instruments for eGFR from a genome-wide association study (GWAS). We conducted two-sample MR analysis for different cardiovascular outcomes using inverse-variance weighted (IVW), weighted median, MR-PRESSO, MR-Egger, and leave-one-out methods. Results: After the most stringent Bonferroni correction (Padjust = 0.01), our findings provided significant evidence for a potential causal relationship between reduced eGFR and heart failure. The IVW result showed statistical significance (OR = 1.009, 95%CI = 1.003~1.015, P = 0.003, P < Padjust). The IVW results for eGFR and coronary artery disease (CAD) (OR = 1.006, 95%CI = 0.998~1.013, P = 0.14), eGFR and cardiovascular disease (CVD) (OR = 1.003, 95%CI = 0.995~1.011, P = 0.45), eGFR and stroke (OR = 1.000, 95%CI = 0.9998~1.0001, P = 0.95), and eGFR and atrial fibrillation (AF) (OR = 1.004, 95%CI = 0.9952~1.0126, P = 0.38) did not suggest any potential causal relationships between eGFR and these cardiovascular outcomes. Conclusion: Our multiple large-scale MR analyses found a significant causal relationship between eGFR and the risk of heart failure, but we did not find any significant causal associations between eGFR and other cardiovascular outcomes.
文章引用:黄烁萱, 缪长宏, 王怡寒, 肖璐, 陈匡. 基于孟德尔随机化探究肾小球滤过率与心血管疾病结局的因果关系[J]. 临床医学进展, 2025, 15(1): 1441-1449. https://doi.org/10.12677/acm.2025.151193

参考文献

[1] Townsend, N., Kazakiewicz, D., Lucy Wright, F., Timmis, A., Huculeci, R., Torbica, A., et al. (2021) Epidemiology of Cardiovascular Disease in Europe. Nature Reviews Cardiology, 19, 133-143. [Google Scholar] [CrossRef] [PubMed]
[2] Bays, H.E., Agarwala, A., German, C., Satish, P., Iluyomade, A., Dudum, R., et al. (2022) Ten Things to Know about Ten Cardiovascular Disease Risk Factors—2022. American Journal of Preventive Cardiology, 10, Article ID: 100342. [Google Scholar] [CrossRef] [PubMed]
[3] Levey, A.S. and Coresh, J. (2012) Chronic Kidney Disease. The Lancet, 379, 165-180. [Google Scholar] [CrossRef] [PubMed]
[4] Heldal, K., et al. (2022) Estimated Glomerular Filtration Rate as a Measurement of Kidney Function. Tidsskr Nor Laegeforen, 141, 115-128.
[5] Cusumano, A.M., Tzanno-Martins, C. and Rosa-Diez, G.J. (2021) The Glomerular Filtration Rate: From the Diagnosis of Kidney Function to a Public Health Tool. Frontiers in Medicine (Lausanne), 8, Article ID: 769335. [Google Scholar] [CrossRef] [PubMed]
[6] Hill, N.R., Fatoba, S.T., Oke, J.L., Hirst, J.A., O’Callaghan, C.A., Lasserson, D.S., et al. (2016) Global Prevalence of Chronic Kidney Disease—A Systematic Review and Meta-Analysis. PLOS ONE, 11, e0158765. [Google Scholar] [CrossRef] [PubMed]
[7] Visseren, F.L.J., Mach, F., Smulders, Y.M., Carballo, D., Koskinas, K.C., Bäck, M., et al. (2021) 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. European Heart Journal, 42, 3227-3337. [Google Scholar] [CrossRef] [PubMed]
[8] Aimo, A., Januzzi, J.L., Vergaro, G., Ripoli, A., Latini, R., Masson, S., et al. (2019) High-Sensitivity Troponin T, NT-proBNP and Glomerular Filtration Rate: A Multimarker Strategy for Risk Stratification in Chronic Heart Failure. International Journal of Cardiology, 277, 166-172. [Google Scholar] [CrossRef] [PubMed]
[9] Wyld, M. and Webster, A.C. (2021) Chronic Kidney Disease Is a Risk Factor for Stroke. Journal of Stroke and Cerebrovascular Diseases, 30, Article ID: 105730. [Google Scholar] [CrossRef] [PubMed]
[10] Verduijn, M., Siegerink, B., Jager, K.J., Zoccali, C. and Dekker, F.W. (2010) Mendelian Randomization: Use of Genetics to Enable Causal Inference in Observational Studies. Nephrology Dialysis Transplantation, 25, 1394-1398. [Google Scholar] [CrossRef] [PubMed]
[11] Burgess, S., Davey Smith, G., Davies, N.M., Dudbridge, F., Gill, D., Glymour, M.M., et al. (2019) Guidelines for Performing Mendelian Randomization Investigations. Wellcome Open Research, 4, 186. [Google Scholar] [CrossRef
[12] Staley, J.R., Blackshaw, J., Kamat, M.A., Ellis, S., Surendran, P., Sun, B.B., et al. (2016) PhenoScanner: A Database of Human Genotype-Phenotype Associations. Bioinformatics, 32, 3207-3209. [Google Scholar] [CrossRef] [PubMed]
[13] Francula-Zaninovic, S. and Nola, I.A. (2018) Management of Measurable Variable Cardiovascular Disease’ Risk Factors. Current Cardiology Reviews, 14, 153-163. [Google Scholar] [CrossRef] [PubMed]
[14] Lee‐Lane, E., Torabi, F., Lacey, A., Fonferko‐Shadrach, B., Harris, D., Akbari, A., et al. (2021) Epilepsy, Antiepileptic Drugs, and the Risk of Major Cardiovascular Events. Epilepsia, 62, 1604-1616. [Google Scholar] [CrossRef] [PubMed]
[15] Spiga, F., et al. (2022) Tools for Assessing Quality and Risk of Bias in Mendelian Randomization Studies: A Systematic Review. International Journal of Epidemiology, 52, 227-249.
[16] Lawlor, D.A., Harbord, R.M., Sterne, J.A.C., Timpson, N. and Davey Smith, G. (2008) Mendelian Randomization: Using Genes as Instruments for Making Causal Inferences in Epidemiology. Statistics in Medicine, 27, 1133-1163. [Google Scholar] [CrossRef] [PubMed]
[17] Bowden, J., Davey Smith, G. and Burgess, S. (2015) Mendelian Randomization with Invalid Instruments: Effect Estimation and Bias Detection through Egger Regression. International Journal of Epidemiology, 44, 512-525. [Google Scholar] [CrossRef] [PubMed]
[18] Zhang, W. and Ghosh, D. (2020) A General Approach to Sensitivity Analysis for Mendelian Randomization. Statistics in Biosciences, 13, 34-55. [Google Scholar] [CrossRef] [PubMed]
[19] Burgess, S. and Thompson, S.G. (2017) Interpreting Findings from Mendelian Randomization Using the MR-Egger Method. European Journal of Epidemiology, 32, 377-389. [Google Scholar] [CrossRef] [PubMed]
[20] Verbanck, M., Chen, C., Neale, B. and Do, R. (2018) Detection of Widespread Horizontal Pleiotropy in Causal Relationships Inferred from Mendelian Randomization between Complex Traits and Diseases. Nature Genetics, 50, 693-698. [Google Scholar] [CrossRef] [PubMed]
[21] Bowden, J. and Holmes, M.V. (2019) Meta‐Analysis and Mendelian Randomization: A Review. Research Synthesis Methods, 10, 486-496. [Google Scholar] [CrossRef] [PubMed]
[22] Afsar, B., Turkmen, K., Covic, A. and Kanbay, M. (2014) An Update on Coronary Artery Disease and Chronic Kidney Disease. International Journal of Nephrology, 2014, Article ID: 767424. [Google Scholar] [CrossRef] [PubMed]
[23] Popolo, A., Autore, G., Pinto, A. and Marzocco, S. (2013) Oxidative Stress in Patients with Cardiovascular Disease and Chronic Renal Failure. Free Radical Research, 47, 346-356. [Google Scholar] [CrossRef] [PubMed]
[24] Nanayakkara, P.W.B. and Gaillard, C.A.J.M. (2010) Vascular Disease and Chronic Renal Failure: New Insights. Netherlands Journal of Medicine, 68, 5-14.
[25] Skalsky, K., Shiyovich, A., Steinmetz, T. and Kornowski, R. (2022) Chronic Renal Failure and Cardiovascular Disease: A Comprehensive Appraisal. Journal of Clinical Medicine, 11, Article No. 1335. [Google Scholar] [CrossRef] [PubMed]
[26] Schefold, J.C., Filippatos, G., Hasenfuss, G., Anker, S.D. and von Haehling, S. (2016) Heart Failure and Kidney Dysfunction: Epidemiology, Mechanisms and Management. Nature Reviews Nephrology, 12, 610-623. [Google Scholar] [CrossRef] [PubMed]
[27] Kelly, D. and Rothwell, P.M. (2019) Disentangling the Multiple Links between Renal Dysfunction and Cerebrovascular Disease. Journal of Neurology, Neurosurgery & Psychiatry, 91, 88-97. [Google Scholar] [CrossRef] [PubMed]
[28] Oh, C., Park, S.K., Jung, J.Y., Choi, J., Ha, E., Lee, E., et al. (2021) Reduced Glomerular Filtration Rate and Risk of Stroke: A Nationwide Cohort Study in South Korea. Journal of Atherosclerosis and Thrombosis, 28, 928-941. [Google Scholar] [CrossRef] [PubMed]
[29] Bos, M.J., Koudstaal, P.J., Hofman, A. and Breteler, M.M.B. (2007) Decreased Glomerular Filtration Rate Is a Risk Factor for Hemorrhagic but Not for Ischemic Stroke. Stroke, 38, 3127-3132. [Google Scholar] [CrossRef] [PubMed]
[30] Ding, W.Y., Gupta, D., Wong, C.F. and Lip, G.Y.H. (2020) Pathophysiology of Atrial Fibrillation and Chronic Kidney Disease. Cardiovascular Research, 117, 1046-1059. [Google Scholar] [CrossRef] [PubMed]
[31] Eisen, A., Haim, M., Hoshen, M., Balicer, R.D., Reges, O., Leibowitz, M., et al. (2016) Estimated Glomerular Filtration Rate within the Normal or Mildly Impaired Range and Incident Non-Valvular Atrial Fibrillation: Results from a Population-Based Cohort Study. European Journal of Preventive Cardiology, 24, 213-222. [Google Scholar] [CrossRef] [PubMed]
[32] Deo, R., Katz, R., Kestenbaum, B., Fried, L., Sarnak, M.J., Psaty, B.M., et al. (2010) Impaired Kidney Function and Atrial Fibrillation in Elderly Subjects. Journal of Cardiac Failure, 16, 55-60. [Google Scholar] [CrossRef] [PubMed]